CanSino Biologics (SHA:688185, HKG:6185) has begun its phase 2/3 clinical trial for its combined vaccine for absorbed diphtheria, tetanus, and acellular pertussis, and enrolled its first patient in its phase 2 trial.
The Tdcp vaccine is indicated for adolescents and adults aged six years old and above, according to a Friday filing with the Hong Kong exchange.
CanSino's vaccine will also help address a vaccination gap for booster shots for Tdcp, according to the filing.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。